3 ms·
The vaccine has 95% efficacy in initial controlled trials. It is almost impossible to reach (within 1%) of that same level of effectiveness in the real world as
by gregwebs 6y ago
The vaccine has 95% efficacy in initial controlled trials. It is almost impossible to reach (within 1%) of that same level of effectiveness in the real world as claimed here. The real world has a big chunk of the population with an immune system that doesn't respond nearly as well to the vaccine (such as the elderly).
Here is an overview of an Israeli study that was finding a more realistic effectiveness of 70% https://dalewharrison.substack.com/p/israeli-vaccination-data https://dalewharrison.substack.com/p/israeli-vaccination-dat...
If anyone has a link to the actual study, please post it! It is really annoying to see news articles posted about studies that don't link to them or even provide any basic information to find the study.
- chkaloon 6y agoOf course it's also possible the outcome in the original clinical study underestimated the efficacy.
- mchusma 6y agoI don't understand your comment. The phase III study was done I'm the real world, not a lab. So it's not surprising we are seeing the same numbers as it rolls out. I'm fact, it would be suprising if it didn't match the studies.
- gregwebs 6y agoThey don't just select from the population at random from these studies. For example the study excludes those over the age of 85 or those that are immunocompormised. You can see more details on the exclusion criteria listed in seciton 5.2 of the Pfizer study: https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591...